Liquid biopsy group releases first open access dataset

The Blood Profiling Atlas in Cancer Consortium (BloodPAC), a nonprofit seeking to spur development of cancer liquid biopsy technology, released to the public its first dataset on its BloodPAC Data Commons.

The BloodPAC Data Commons will include freely available data from circulating tumor cells, circulating tumor DNA, proteins, tumor-associated autoantibodies, exosome assays and associated clinical data and sample quality assurance protocols from more than 30 companies, hospitals, universities, nonprofits and government agencies. The consortium also said it worked with FDA’s Center for Devices and Radiological Health to develop data submission standards for its members.

Notable industry members of BloodPAC include AstraZeneca plc (LSE:AZN; NYSE:AZN), Celgene Corp. (NASDAQ:CELG), Eli Lilly and Co. (NYSE:LLY), Novartis AG (NYSE:NVS; SIX:NOVN) and Pfizer Inc. (NYSE:PFE).